Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

This study provided a comprehensive assessment of the efficacy and prognostic factors of ICI rechallenge in RM-NPC patients who failed prior anti-PD-1 immunotherapy, and developed a prognostic model which could identify candidates for ICI rechallenge. Further prospective trials are warranted to confirm and expand these findings.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-01-27
DOI
https://doi.org/10.1007/s00262-025-04258-y
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

Guoying Liu, Jie Wu, Lisheng Zheng, Weixin Bei et al.
Cancer Immunology Immunotherapy
Cancer Immunotherapy and Biomarkers
article

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study

Guoying Liu, Jie Wu, Lisheng Zheng, Weixin Bei, Shuhui Dong, Yaofei Jiang, Yanqun Xiang, Zhenyu Zhang
article en

Abstract

This study provided a comprehensive assessment of the efficacy and prognostic factors of ICI rechallenge in RM-NPC patients who failed prior anti-PD-1 immunotherapy, and developed a prognostic model which could identify candidates for ICI rechallenge. Further prospective trials are warranted to confirm and expand these findings.

Cancer Immunology ImmunotherapyVol. 75(2)
Central South University (CN), Nanchang University (CN), Sun Yat-sen University (CN), First Affiliated Hospital of Jiangxi Medical College (CN), Ministry of Education (SA), Sun Yat-sen Memorial Hospital (CN), Guangdong Academy of Medical Sciences (CN), Sun Yat-sen University Cancer Center (CN), First Affiliated Hospital of Nanchang University (CN)
Natural Science Foundation of Xinjiang Province, National Natural Science Foundation of China, Nanchang University, Natural Science Foundation of Xinjiang
Good health and well-being
Openalex Percentile: Top 77%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study — Guoying Liu, Jie Wu, et al. · Cancer Immunology Immunotherapy (2026) | TGRS Research Map | TGRS